Dabigatran and kidney disease: A bad combination

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 9, 2013, Pages 1591-1597

  Knauf, Felix ^a   Chaknos, C Michael ^b   Berns, Jeffrey S ^b   Perazella, Mark A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CARBON; ACTIVATED PROTHROMBIN COMPLEX; DABIGATRAN; ENOXAPARIN; FRESH FROZEN PLASMA; GLUCURONIC ACID; LOW MOLECULAR WEIGHT HEPARIN; MULTIDRUG RESISTANCE PROTEIN; NOVO NORDISK; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; UNCLASSIFIED DRUG; WARFARIN;

BLEEDING; BLOOD CLOTTING TIME; CHRONIC KIDNEY DISEASE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG MONITORING; HEMODIALYSIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY DISEASE; KIDNEY FUNCTION; PARTIAL THROMBOPLASTIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH LAVAGE; THROMBOEMBOLISM;

ANTIDOTES; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; CHARCOAL; DRUG MONITORING; HEMORRHAGE; HUMANS; KIDNEY DISEASES; PLASMA; RENAL REPLACEMENT THERAPY;

EID: 84883737026     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01260213     Document Type: Review

References (43)

1. Hyers TM: Management of venous thromboembolism: past, present, and future. Arch Intern Med 163: 759-768, 2003
2. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS: 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 57: e101-e198, 2011
3. Ansell J: Warfarin versus new agents: Interpreting the data. Hematology (Am Soc Hematol Educ Program) 2010: 221-228, 2010
4. Wartak SA, Bartholomew JR: Dabigatran: Will it change clinical practice? Cleve Clin J Med 78: 657-664, 2011
5. Radecki RP: Dabigatran: Uncharted waters and potential harms. Ann Intern Med 157: 66-68, 2012
6. Hankey GJ, Eikelboom JW: Dabigatran etexilate: A new oral thrombin inhibitor. Circulation 123: 1436-1450, 2011
7. Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W: Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 45: 1757-1766, 2002
8. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361: 1139-1151, 2009
9. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kalebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Buller HR; RE-MODEL Study Group: Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The RE-MODEL randomized trial. J Thromb Haemost 5: 2178-2185, 2007
10. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Buller HR; RE-NOVATE Study Group: Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial. Lancet 370: 949-956, 2007
11. Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Schnee JM, Friedman RJ; RE-NOVATE II Study Group: Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost 105: 721-729, 2011
12. Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA; RE-MOBILIZE Writing Committee: Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 24: 1-9, 2009
13. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ; RE-COVER Study Group: Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361: 2342-2352, 2009
14. Food and Drug Administration: FDA Drug Safety Podcast for Healthcare Professionals: Safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate mesylate) Available at: www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm283151.htm. Accessed January 2013
15. Radecki RP: Dabigatran: uncharted waters and potential harms. Ann Intern Med 157: 66-68, 2012
16. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W: The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64: 292-303, 2007
17. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W: The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36: 386-399, 2008
18. Walenga JM, Adiguzel C: Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract 64: 956-967, 2010
19. Jungbauer L, Dobias C, Stollberger C, Weidinger F: The frequency of prescription of P-glycoprotein-affecting drugs in atrial fibrillation. J Thromb Haemost 8: 2069-2070, 2010
20. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A: Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103: 1116-1127, 2010
21. Liesenfeld KH, Schafer HG, Trocóniz IF, Tillmann C, Eriksson BI, Stangier J: Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: A population model analysis. Br J Clin Pharmacol 62: 527-537, 2006
22. Stangier J, Feuring M: Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 23: 138-143, 2012
23. Wychowski MK, Kouides PA: Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother 46: e10, 2012
24. Harinstein LM, Morgan JW, Russo N: Treatment of dabigatran-associated bleeding: Case report and review of the literature [Published online ahead of print November 16, 2012]. J Pharm Pract doi: 10.1177/0897190012465955
25. Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW: Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 119: 2172-2174, 2012
26. Chen BC, Viny AD, Garlich FM, Basciano P, Howland MA, Smith SW, Hoffman RS, Nelson LS: Hemorrhagic complications associated with dabigatran use. Clin Toxicol (Phila) 50: 854-857, 2012
27. Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, Bendszus M, Heiland S, van Ryn J, Veltkamp R: Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 42: 3594-3599, 2011
28. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G: Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141: e44S-e88S, 2012
29. Lambourne MD, Eltringham-Smith LJ, Gataiance S, Arnold DM, Crowther MA, Sheffield WP: Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. J Thromb Haemost 10: 1830-1840, 2012
30. Pragst I, Zeitler SH, Doerr B, Kaspereit FJ, Herzog E, Dickneite G, van Ryn J: Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost 10: 1841-1848, 2012
31. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M: Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124: 1573-1579, 2011
32. Key NS, Negrier C: Coagulation factor concentrates: past, present, and future. Lancet 370: 439-448, 2007
33. Khoo TL, Weatherburn C, Kershaw G, Reddel CJ, Curnow J, Dunkley S: The use of FEIBA (R) in the correction of coagulation abnormalities induced by dabigatran. Int J Lab Hematol 35: 222-224, 2013
34. Chang DN, Dager WE, Chin AI: Removal of dabigatran by hemodialysis. Am J Kidney Dis61: 487-489, 2013
35. Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G: Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaaroxaban: A randomized crossover ex viv study in healthy volunteers. Thromb Haemost 108: 217-224, 2012
36. van Ryn, Litzenburger T, Waterman A, Canada K, Hauel N, Sarko C, Kroe-Barrett R, Park J: Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in-vitro and in-vivo models. Presented at the 60th Annual Scientific Session and Expo of the American College of Cardiology, New Orleans, LA, April 2-5, 2011
37. van Ryn JLT, Schurer J: Reversal of anticoagulant activity of dabigatran and dabigatran-induced bleeding in rats by a specific antidote (antibody fragment). Presented at the 85th Scientific Sessions-Resuscitation Science Symposium (ReSS) of the American Heart Association, Los Angeles, CA, November 3-6, 2012
38. Stangier J, Rathgen K, Stahle H, Mazur D: Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: An open-label, parallel-group, single-centre study. Clin Pharmacokinet 49: 259-268, 2010
39. Stangier J, Stahle H, Rathgen K, Fuhr R: Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 47: 47-59, 2008
40. Wagner FPH, Formella S, Wiegert E, Moschetti V, Khadzhynov D, Clemens A: Effective elimination of dabigatran with haemodialysis: a phase I single centre study in patients with end-stage renal disease. Presented at the 84th Scientific Sessions 2011 of the American Heart Association, Orlando, FL, November 12-16, 2011
41. Hartter STM, Liesenfeld K-H, Nehmiz G, Moschetti V, Formella S, Khadzhynov D, Wagner F, Peters H: Investigation of the elimination of dabigatran by haemodialysisin patients with end stage renal disease. Presented at 113th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, National Harbor, MD, March 12-17, 2012
42. Lange J, Thiel C, Thiel K, Klingert W, Klingert K, Konigsrainer A, Formella S, Clemens A, van Ryn J, Schenk M: Acceleration of dabigatran elimination by activated charcoal perfusion and hemodialysis in a pig model. Presented at the 54th American Society of Hematology Annual Meeting and Exposition, Atlanta, GA, December 8-11, 9, 2012
43. Wanek MR, Horn ET, Elapavaluru S, Baroody SC, Sokos G: Safe use of hemodialysis for dabigatran removal before cardiac surgery. Ann Pharmacother 46: e21, 2012